Skip to content

Avanos Medical AVNS Depreciation

Depreciation at other companies

Medtronic logo
MedtronicMDT
Baxter International logo
Baxter InternationalBAX
Charles River Laboratories logo
Charles River LaboratoriesCRL
Henry Schein logo
Henry ScheinHSIC

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B-1.2%
Enterprise value$1.24B+3.0%
P/S1.6×-0.1×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's depreciation?
Avanos Medical (AVNS) reported depreciation of $5.6M in Q1 2026.
How has Avanos Medical's depreciation changed year-over-year?
Avanos Medical's depreciation increased by 24.4% year-over-year, from $4.5M to $5.6M.
What is the long-term trend for Avanos Medical's depreciation?
Over 4 years (2021 to 2025), Avanos Medical's depreciation has grown at a 3.8% compound annual growth rate (CAGR), from $17M to $19.7M.